BICX supply chain intelligence for BioCorRx Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
BioCorRx Inc. (BICX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ALPINE-CREEK-CAPITAL-PARTNERS-LLC | ALPINE-CREEK-CAPITAL-PARTNERS-LLC | 90% | On December 10, 2015, the Company entered into a royalty agreement with Alpine Creek Capital Partners LLC |
| JPL-LLC | JPL-LLC | 90% | In consideration for the Connecticut License the Company received from JPL: (i) an up-front license fee of $350,000 |
| MEDICAL-CORPORATION | MEDICAL-CORPORATION | 90% | Management and other administrative services to the Medical Corporation. These services include billing, collection of accounts receivable, accounting, management and human resource functions. |
| BIOCORRX-PHARMACEUTICALS-INC | BIOCORRX-PHARMACEUTICALS-INC | 80% | In 2018, BioCorRx Pharmaceuticals, Inc. began operating activities |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| TWO-CUSTOMERS | TWO-CUSTOMERS | 92% | The Company’s revenues earned from sale of products and services for the three months ended March 31, 2026 included 99 % from two customers of the Company’s total revenues. |
| CERECARE-LLC | CERECARE-LLC | 90% | Distributor Agreement with CereCare, LLC, dated December 8, 2017 |
| FRESH-START-PRIVATE-INC | FRESH-START-PRIVATE-INC | 85% | The consolidated financial statements include the accounts of: (i) BioCorRx Inc. and its wholly owned subsidiary, Fresh Start Private, Inc., (ii) its majority owned subsidiary, BioCorRx Pharmaceutica… |
| USWM-LLC | USWM-LLC | 85% | to customers. The distribution rights income consists of the income recognized from the amortization of distribution agreements entered into for its products. The membership/program fees are generate… |
| BIOCORRX-PHARMACEUTICALS-INC | BIOCORRX-PHARMACEUTICALS-INC | 62% | NOTE 8 – INTANGIBLE ASSETS The Company’s intangible assets consisted of the following at March 31, 2026 and December 31, 2025: March 31, December 31, 2026 2025 Patents $ - $ 15,200 Trademark 249,500 … |
| CAROLYN-LUCIDO-CRT-LLC | CAROLYN-LUCIDO-CRT-LLC | 62% | NOTE 13 - ROYALTY OBLIGATIONS, NET In March 2019, the Company entered into two Subscription and Royalty Agreements (the “Subscription and Royalty Agreements”). One was with Louis and Carolyn Lucido C… |
| JOSEPH-DESANTO-MD-INC | JOSEPH-DESANTO-MD-INC | 62% | n, acquired from Alpine Creek the rights to the subscription and royalty agreement by and between the Company and Alpine Creek. As of December 31, 2025 and 2024, the Company’s related party payable w… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| BICX-DEBT | Debt stack $2.1M | 90% | Market cache reports total debt of $2.1M. |
| BICX-DEBT-8191 | Warrants outstanding: 0.35 | 90% | xbrl warrant detail from xbrl 2025-07-29. |
| BICX-DEBT-8192 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |